Mental health platform Headway today announced it has raised $70 million in a Series B funding round. Andreessen Horowitz led the round with participation from Thrive, GV and Accel.
Coming in six months after its $26 million Series A round, Headway now boasts $103 million in total funding and a new valuation of $750 million.
WHAT THEY DO
Headway operates a platform connecting patients to in-...
Novartis has published results from a clinical trial of Pear Therapeutics' new digital therapeutic for schizophrenia, and the results don't paint a rosy picture.
The single-blinded 112-person trial found no difference between the Pear app and a placebo app in any outcome measure, including the primary outcome measure of reducing schizophrenia symptoms. However, the trial did further establish the...
Pear Therapeutics has inked a deal with pharma company Novartis to work together on the development of two digital therapeutics for multiple sclerosis and schizophrenia. It’s the first time a pharma company has made a development deal with a digital therapeutic, according to Pear.
“We have been in discussions for many months now with the [Novartis Institutes for BioMedical Research] group at...
New York-based ClassPass, a virtual fitness membership network, has raised $70 million in Series C funding in a round led by Temasek. Existing investors Acequia Capital, CRV, General Catalyst, GV, M13 and Thrive also contributed to the funding, which ClassPass will use to expand operations and develop new products.
ClassPass, which was founded in 2013, uses an app to connect users to fitness...
Pear Therapeutics, a Boston and San Francisco-based developer of digital strategies to address a broad range of mental health conditions, has released results of a study showing promising engagement with its program Thrive, which uses a smartphone app along with medication to treat patients with schizophrenia, schizoaffective disorder and bipolar disorder.
Thrive offers 24/7 patient monitoring...
